26th March 2020
The LigandTracer instrument uses technology that can help accelerate and improve drug discovery in the fight against COVID-19
Ridgeview Instruments AB offer instruments and software for studying biological interactions in real-time.
Their cell-based interaction technology LigandTracer is a highly flexible platform that allows you to perform a broad range of interaction studies.
Drug development is often a long and costly process with a high degree of uncertainty, and Ridgeview believe that new strategies that can accelerate and improve drug discovery are fundamental in finding successful treatments in the fight against COVID-19.
One critical element in drug discovery is understanding how the potential compounds bind to their target, which can be also understood by measuring the affinity value (KD). Introducing time into interaction measurements can also be of great value for the development of new drugs, as well as where information about the association and dissociation rates can be obtained, and information about dosage and duration of effect.
Studying the binding of new potential compounds in real-time on living cells may be more relevant because the effect of the new drug is evaluated in the true living environment. This can help to predict unexpected outcomes in in vivo experiments.
Ridgeview Instruments AB is offering their LigandTracer technology for use in COVID-19 research.
LigandTracer is often used in antibody development, immunologic research and nanoparticle characterisation.
The company asks that return shipping must be paid by the user.
ASK: Research contributors needed for CON-VICE study
University of Luxembourg needs European researchers to get in touch
OFFER: Funding available for COVID-19 research
Fondation Air Liquide are looking to fund European projects
ASK: Supporting the immunocompromised
Partners sought to advance neutralising antibody